Recombinant Proteins iso9001 ISO13485
搜索
 > 【TRAIL R1】重组蛋白信息

TRAIL R1信息

英文名称:Tumor necrosis factor receptor superfamily member 10A
中文名称:肿瘤坏死因子受体超家族成员10A
靶点别称:TRAIL-R1,Tumor necrosis factor receptor superfamily member 10A,DR4,TRAILR1,APO2,TNFRSF10A,TNF Receptor Superfamily Member 10a,Tumor Necrosis Factor Receptor Superfamily, Member 10a,Death Receptor 4,TRAIL Receptor 1,Cytotoxic TRAIL Receptor,CD261 Antigen,T
上市药物数量:0
临床药物数量:6
最高研发阶段:临床三期

TRAIL R1产品列表

产品库
物种
属性
货号 物种 产品描述 蛋白结构 纯度 活性
TR1-H5228
Human
Human TRAIL R1 / DR4 / TNFRSF10A Protein, His Tag
TR1-H5254
Human
Human TRAIL R1 / DR4 / TNFRSF10A Protein, Fc Tag
 
评论(1)
TR1-H5254|Human TRAIL R1 / DR4 / TNFRSF10A Protein, Fc Tag
  1. 182XXXXXXX2
  2. 2人赞
  3. 购买TNFRSF10A的目的是用来测定Binding的,首先测定了一下纯度,从附件中SEC的结果也可以看出纯度还不错,有94.8%
  4. >
  5. 2019-09-30
 

TRAIL R1 分子别名

TNFRSF10A,TRAIL-R1,CD261,APO2,DR4

TRAIL R1 分子背景

Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) is also known as TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), Death receptor 4 (DR4), CD261 and APO2, which belongs to TNF superfamily. TRAILR1 / TNFRSF10A contains 1 death domain and 3 TNFR-Cys repeats. TNFRSF10A / DR4 is widely expressed and high levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells. APO2 / TNFRSF10A is receptor for the cytotoxic ligand TNFSF10 / TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAILR-1 / DR4 / CD261 promotes the activation of NF-kappa-B.

TRAIL R1 参考文献

TRAIL R1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Circularly permuted TRAIL (Beijing Sunbio Biotech) 临床三期 北京沙东生物技术有限公司 多发性骨髓瘤 详情
HLX56 HLX56; HLX-56 临床一期 上海复宏汉霖生物技术股份有限公司 实体瘤 详情
Eftozanermin alfa APG-350; APG-880; ABBV-621; PR-1625011 临床一期 艾伯维 血液肿瘤, 多发性骨髓瘤 详情
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) 临床三期 深圳未名新鹏生物医药有限公司 肿瘤 详情
Dulanermin (Shanghai GeBaiDe) 临床三期 上海歌佰德生物技术有限公司 非小细胞肺癌 详情
Mapatumumab TRAIL-R1; DR4-mAB; HGS-1012; HGS-ETR1; TRM-1 临床二期 Cambridge Antibody Technology 肝癌, 多发性骨髓瘤, 结直肠癌, 非霍奇金淋巴瘤, 肝细胞癌, 非小细胞肺癌, 宫颈癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定